price
RE
NASDAQ · REPL
Replimune Group, Inc.
Healthcare · Biotechnology
$13.03
Down-$0.09 (-0.72%)
Updated Sep 16, 2026, 3:02 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 774.6M
- P/E ratio
- -3.23
- Dividend yield
- 0.00%
- 52-week range
- $1.50 – $16.33
- Volume
- 2.23M
- Avg. volume
- 5.08M
Price performance
REPL price history
1M range · 20 trading sessions · Daily adjusted prices
REPL closed at $13.03 after 20 trading sessions, down 16.37% for the selected period.
- Last close
- $13.03
- Period change
- -16.37%
- Period low
- $12.92
- Period high
- $15.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $12.98 | $13.06 | $12.46 | $13.03 | 2.23M |
| Sep 14, 2026 | $12.90 | $13.645 | $12.79 | $13.11 | 2.35M |
| Sep 11, 2026 | $13.33 | $13.74 | $12.40 | $12.92 | 4.09M |
| Sep 10, 2026 | $14.47 | $14.47 | $13.21 | $13.24 | 3.65M |
| Sep 9, 2026 | $14.54 | $14.76 | $14.30 | $14.45 | 1.07M |
| Sep 8, 2026 | $14.90 | $14.99 | $14.61 | $14.77 | 1.5M |
| Sep 4, 2026 | $15.22 | $15.3313 | $14.80 | $15.04 | 910.23K |
| Sep 3, 2026 | $15.99 | $16.025 | $15.02 | $15.29 | 1.35M |
| Sep 2, 2026 | $15.65 | $16.33 | $15.50 | $15.98 | 1.99M |
| Sep 1, 2026 | $15.24 | $15.71 | $14.97 | $15.67 | 1.78M |
| Aug 31, 2026 | $15.36 | $15.52 | $14.90 | $15.30 | 1.7M |
| Aug 28, 2026 | $15.402 | $15.87 | $15.40 | $15.50 | 2.39M |
| Aug 27, 2026 | $15.76 | $16.15 | $15.555 | $15.60 | 1.67M |
| Aug 26, 2026 | $15.60 | $15.99 | $15.045 | $15.88 | 2.38M |
| Aug 25, 2026 | $14.63 | $15.89 | $14.59 | $15.80 | 3.14M |
| Aug 24, 2026 | $14.63 | $15.04 | $14.11 | $14.71 | 2.08M |
| Aug 21, 2026 | $13.88 | $14.98 | $13.81 | $14.77 | 2.97M |
| Aug 20, 2026 | $14.55 | $14.765 | $13.92 | $14.05 | 4.3M |
| Aug 19, 2026 | $15.17 | $15.64 | $14.73 | $14.81 | 3.44M |
| Aug 18, 2026 | $14.60 | $15.615 | $14.50 | $15.58 | 2.25M |
Latest REPL news
The latest Smart Investors Daily articles mentioning REPL.
Stock researchResearch & News · Competitors
Loading stock research…

